The National Cancer Institute (NCI) awarded a $431,968 Project Grant (CFDA 93.396 - Cancer Biology Research) to Baylor College of Medicine to elucidate how the MYCN oncogene drives metabolic reprogramming and immune suppression in high-risk neuroblastoma. The 5-year research project, with an award date of August 15, 2024 and an end date of July 31, 2029, aims to understand how MYCN-driven tumor metabolism depletes cysteine, a critical nutrient for T cell activation, thereby creating an...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...
The National Cancer Institute (NCI) awarded a $2,186,372 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of California Irvine (UC Irvine) to fund a 5-year program titled "Tipping Points in Cancer." The program will address fundamental questions about cancer initiation and progression through three research projects:
Investigating the origins of primary therapeutic resistance and ways to improve existing therapies for chronic myeloid leukemia using an...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $1,011,207 to Transcode Therapeutics, Inc. to conduct Phase I clinical testing of a novel first-in-class therapy against metastatic cancer. The funded research focuses on the development and evaluation of Transcode's therapeutic agent, MN-anti-miR10b, which targets the metastasis-driving microRNA-10b for the selective eradication of metastatic tumor...
The National Cancer Institute (NCI) awarded a $399,709 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Sieyax LLC, a woman-owned small business located in Broomfield, Colorado. The purpose of this 1-year grant is to develop a novel therapeutic for treating medulloblastoma, the most common malignant brain tumor in children. Specifically, the project aims to optimize the synthesis and evaluate the drug metabolism, pharmacokinetics, and potential toxicity of a lead...
The National Cancer Institute (NCI) awarded a $607,634 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic Jacksonville, a nonprofit healthcare organization, to conduct research on "Generating Synthetic Lethality in Glioblastoma with a First-in-Class Non-Muscle Myosin II Inhibitor." The research aims to uncover the mechanisms behind the synergistic effects between a novel molecular inhibitor (MT-125), signal transduction inhibitors, and radiation therapy in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $452,549.00 to Emory University to conduct research on targeting intrinsic and extrinsic features of MYC-driven osteosarcoma. The key objectives are to:
Comprehensively characterize and genetically perturb cross-species molecular features of MYC-hyperactivated human and murine osteosarcoma tumors to identify intrinsic and extrinsic signatures and cell-cell...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $268,590 to The Johns Hopkins University to investigate the effects of the oncogene MYC on protein translation dynamics and ribosome collision-induced signaling in cancer cells. The central hypothesis is that MYC overexpression leads to increased apoptosis in the presence of drugs that induce ribosome collisions. The research aims to 1) study the impacts of MYC expression on protein...
The National Cancer Institute (NCI) awarded a $558,333 Cooperative Agreement (CFDA 93.396 - Cancer Biology Research) to Clemson University to develop computational models and experimental systems for "cell state network-directed" cancer therapies, with a focus on glioblastoma multiforme (GBM). The project aims to characterize GBM cell state networks and their responses to single and combination drug treatments using in vivo-like tumor chip systems and advanced single-cell analysis...
The National Cancer Institute (NCI) awarded a $1,217,906 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Cosmyc Inc. of Dover, DE. The grant, with a funding period from June 18, 2024 to May 31, 2025, will support research into the therapeutic inhibition of the MYC:TRRAP interaction in cancer. This fundamental cancer biology research aims to provide critical insights into the molecular and cellular mechanisms underlying cancer development and progression, with the potential to lead to new diagnostic, preventive, or therapeutic approaches. The award to the for-profit organization Cosmyc Inc. reflects the program's focus on funding innovative, high-risk investigations that can significantly advance the understanding of cancer biology.